After more than 20 years of failed strategies to improve survival rates for locally advanced lung cancers, checkpoint inhibitors have revolutionized therapy, but prognoses still lag behind other tumor types. During the ASCO20 Virtual Education Program, Mark G. Kris, MD, FASCO, a thoracic medical oncologist at Memorial…
Investigators uncovered critical issues related to health equity and aging that may have broad implications for cancer trials among breast cancer survivors receiving aspirin, according…
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discusses an exploratory analysis from the FLAURA2 study, which indicates that baseline levels of plasma EGFR…
In a French noncomparative phase II trial, investigators established limited activity of FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus durvalumab or durvalumab/tremelimumab in the second-lin…
Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center, discusses the benefits to patients with neoadjuvant therapy in advanced, inoperable breast…
Exposure to propofol was associated with an increased risk of impairment in reaction time/processing speed at 1 year after treatment in children with high-risk B-cell…
A preclinical study suggests that the addition of a component of the ketogenic diet—a preketone dietary supplement—to immunotherapy may potentially be effective in treating prostate…
Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center, discusses the benefits to patients with neoadjuvant therapy in advanced, inoperable breast…
A systematic review and meta-analysis found that neoadjuvant chemoimmunotherapy was associated with improved event-free survival and pathologic complete response compared with neoadjuvant chemotherapy…
Investigators have uncovered persistent racial and social disparities that may impede access to autologous hematopoietic cell transplantation for some patients with multiple myeloma.
The FDA has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of HER2-overexpressing breast cancer and gastric or gastroesophageal junction adenocarcinom…
